|
1
|
Barton AE, Borchard G, Wacker MG, Pastorin G, Saleem IY, Chaudary S, Elbayoumi T, Zhao Z, Flühmann B. Need for Expansion of Pharmacy Education Globally for the Growing Field of Nanomedicine. Pharmacy 2022; 10:pharmacy10010017. [PMID: 35202067 PMCID: PMC8878512 DOI: 10.3390/pharmacy10010017] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 01/10/2022] [Accepted: 01/13/2022] [Indexed: 11/26/2022] Open
Abstract
The emerging landscape of nanomedicine includes a wide variety of active pharmaceutical ingredients and drug formulations. Their design provides nanomedicines with unique features leading to improved pharmacokinetics and pharmacodynamics. They are manufactured using conventional or biotechnological manufacturing processes. Their physical characteristics are vastly different from traditional small-molecule drugs. Pharmacists are important members of the multi-disciplinary team of scientists involved in their development and clinical application. Consequently, their training should lead to an understanding of the complexities associated with the production and evaluation of nanomedicines. Therefore, student pharmacists, post-doctoral researchers, and trainees should be given more exposure to this rapidly evolving class of therapeutics. This commentary will provide an overview of nanomedicine education within the selection of pharmacy programs globally, discuss the current regulatory challenges, and describe different approaches to incorporate nanomedicine science in pharmacy programs around the world.
Collapse
Affiliation(s)
- Amy E. Barton
- Vifor Pharma Group, Vifor Pharma Management Ltd., Flughofstrasse 61, 8152 Glattbrugg, Switzerland;
- Correspondence: ; Tel.: +41-58-851-80-00
| | - Gerrit Borchard
- Section of Pharmaceutical Sciences, School of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva,1, Rue Michel Servet, 1211 Geneva, Switzerland;
| | - Matthias G. Wacker
- Department of Pharmacy, Faculty of Science, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; (M.G.W.); (G.P.)
| | - Giorgia Pastorin
- Department of Pharmacy, Faculty of Science, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore; (M.G.W.); (G.P.)
| | - Imran Y. Saleem
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK; (I.Y.S.); (S.C.)
| | - Shaqil Chaudary
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UK; (I.Y.S.); (S.C.)
| | - Tamer Elbayoumi
- Department of Pharmaceutical Sciences & Nanomedicine Center of Excellence, College of Pharmacy Glendale Campus, Midwestern University, 19555 N. 59th Avenue, Glendale, AZ 85308, USA;
| | - Zhigang Zhao
- Department of Clinical Pharmacy, School of Pharmacy, Capital Medical University, No.10, Xitoutiao, You’anmen Wai, Fengtai District, Beijing 100069, China;
- Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, 119 Nansihuan Xi Lu, Fengtai District, Beijing 100070, China
| | - Beat Flühmann
- Vifor Pharma Group, Vifor Pharma Management Ltd., Flughofstrasse 61, 8152 Glattbrugg, Switzerland;
| |
Collapse
|
|
2
|
Priglinger E, Maier J, Chaudary S, Lindner C, Wurzer C, Rieger S, Redl H, Wolbank S, Dungel P. Photobiomodulation of freshly isolated human adipose tissue-derived stromal vascular fraction cells by pulsed light-emitting diodes for direct clinical application. J Tissue Eng Regen Med 2018; 12:1352-1362. [DOI: 10.1002/term.2665] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Revised: 11/29/2017] [Accepted: 03/21/2018] [Indexed: 01/15/2023]
Affiliation(s)
- E. Priglinger
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - J. Maier
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - S. Chaudary
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - C. Lindner
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - C. Wurzer
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - S. Rieger
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - H. Redl
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - S. Wolbank
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| | - P. Dungel
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology; AUVA Research Center; Vienna Austria
- Austrian Cluster for Tissue Regeneration; Vienna Austria
- Liporegena GmbH; Breitenfurt Austria
| |
Collapse
|
|
5
|
Abstract
Eight childhood cancer patients with herpes zoster were serially tested for the presence of varicella-zoster virus in blood. Cell cultures of leukocyte-rich plasma from four patients were positive for the virus. In this study viremia was clearly related to dissemination of dermal lesions-the spread of zoster lesions outside an infected dermatome. The child with the longest viremic phase, five days, had the longest and most severe course of skin dissemination, as well as biochemical evidence of hepatitis. One patient with viremia had advanced embryonal carcinoma and died of disseminated tumor before her clinical course could be evaluated. These observations, the first to document a viremic phase for herpes zoster in immunosuppressed children, furnish an added criterion for evaluation of antiviral drugs and live-virus vaccines in the treatment and prevention of varicella-zoster infections.
Collapse
|